Search Result

Pathways Recommended:	Anti-infection

Results for "

hepatitis B virus infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HBV (36) HCV (11) Apoptosis (2) Bacterial (3) Branched Chain Amino Acid Transaminase (BCAT) (1) Carboxylesterase (CES) (1) Claudin (1) DGK (1) DNA/RNA Synthesis (4) Endogenous Metabolite (1) ERK (1) Fungal (2) HCV Protease (4) HIV (3) HPV (1) IFNAR (3) Influenza Virus (1) Interleukin Related (3) JNK (1) Liposome (1) NF-κB (3) Nucleoside Antimetabolite/Analog (1) p38 MAPK (1) Parasite (2) PD-1/PD-L1 (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) Small Interfering RNA (siRNA) (2) STING (1) Toll-like Receptor (TLR) (3) Transmembrane Glycoprotein (2) Virus Protease (3)
By Research Areas:	Cancer (7) Infection (55) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (3)
Oligonucleotides:	Adenosine (1) Nucleoside Analogs (2) Phospholipids (1) siRNA drugs (3) Cytidine (1) siRNAs (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: Hepatitis E Virus (HEV) HCV HBV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109137

Selgantolimod 1 Publications Verification GS-9688	Toll-like Receptor (TLR) HBV	Infection
Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection .

HY-N3519

Platycodin D3 1 Publications Verification	HCV Branched Chain Amino Acid Transaminase (BCAT) Interleukin Related NF-κB ERK p38 MAPK JNK	Infection Inflammation/Immunology
Platycodin D3 is a triterpenoid saponin that can be found in Platycodon grandiflorum. Platycodin D3 exhibits multiple activities including anti-inflammation, regulation of airway mucus secretion, improvement of asthmatic airway inflammation and remodeling, and inhibition of hepatitis C virus (HCV) replication. The IC₅₀ value of Platycodin D3 against HCV NS5B RNA-dependent RNA polymerase is 8 μg/mL. Platycodin D3 can be used in studies related to asthma, hepatitis C virus infection and inflammatory diseases .

HY-N0444

Rubiadin	Reactive Oxygen Species (ROS) NF-κB HBV Apoptosis Bacterial Fungal Parasite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .

HY-109195

Vebicorvir 2 Publications Verification ABI-H0731	HBV	Infection Inflammation/Immunology
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC₅₀s from 1.84 μM to 7.3 μM .

HY-147255

Canocapavir ZM-H1505R	HBV	Infection
Canocapavir (ZM-H1505R) is an orally active HBV core protein-targeting antiviral agent. Canocapavir binds to the hydrophobic pocket at the dimer-dimer interface of HBV core protein (HBc), stimulating intracellular accumulation of nonfunctional HBV capsids, disrupting viral replication. Canocapavir interferes with the interaction between HBc and HBV large surface protein, resulting in diminished production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection .

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-148560A

trans-ccc_R08	HBV DNA/RNA Synthesis	Infection
trans-ccc_R08 (Compound 1-B) is a cccDNA inhibitor with anti-HBV activity, with an IC₅₀ of 0.14 μM for HBeAg and an IC₅₀ of 0.08 μM for HBsAg in in vitro assays. trans-ccc_R08 inhibits covalently closed circular DNA (cccDNA). trans-ccc_R08 is applicable to research related to hepatitis B virus infection .

HY-P99693

Lenvervimab GC1102	HBV	Infection
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .

HY-145638A

Xalnesiran sodium RO7445482 sodium	HBV	Infection
Xalnesiran (RO7445482) sodium is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome . Xalnesiran sodium can be used for the research of chronic hepatitis B infection .

HY-148560

ccc_R08 1 Publications Verification	HBV DNA/RNA Synthesis	Infection
ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection .

HY-P10056

HEP-1 Human ezrin peptide (324-337)	HIV HCV HPV Influenza Virus Interleukin Related	Infection Inflammation/Immunology
HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases .

HY-147266

Elebsiran sodium VIR-2218 sodium	Small Interfering RNA (siRNA) HBV	Infection
Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .

HY-142989

1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine	Liposome HIV HCV HBV	Infection Cancer
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia .

HY-10242

Ciluprevir BILN 2061; BILN 2061ZW	HCV HCV Protease DNA/RNA Synthesis	Infection
Ciluprevir (BILN 2061; BILN 2061ZW) is an orally active macrocyclic peptide inhibitor of hepatitis C virus (HCV)NS3 protease, with an IC₅₀ of 3 nM. Ciluprevir has Kᵢ values of 0.66 nM and 0.30 nM against genotypes 1b and 1a, respectively. Ciluprevir inhibits HCV RNA replication with an EC₅₀ of 1.2 nM, and its EC50 values against genotypes 1b and 1a are 3 nM and 4 nM, respectively. Ciluprevir shows no significant inhibition against human leukocyte elastase and hepatic cathepsin B. Ciluprevir can be used for genotype 1 HCV infection .

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .

HY-W352344

2'-Deoxy-L-adenosine	HBV	Infection
2'-Deoxy-L-adenosine is an orally active synthon for modified oligodeoxyribonucleotides. 2'-Deoxy-L-adenosine is a potent, specific and selective inhibitor of the replication of hepatitis B virus (HBV) as well as the closely related duck and woodchuck hepatitis viruses (WHV) .

HY-16680

Helioxanthin 8-1 Helioxanthin analogue 8-1	HBV	Infection
Helioxanthin 8-1(Helioxanthin analogue 8-1) is an anti-HBV agent. Helioxanthin 8-1 exhibits anti-hepatitis B virus activity in both in vitro human hepatitis B virus models and animal models. Helioxanthin 8-1 inhibits the synthesis of duck hepatitis B virus (DHBV) DNA, covalently closed circular DNA, RNA and proteins, thereby blocking DHBV replication. Helioxanthin 8-1 shows higher cytotoxicity in virus-induced cells than in non-induced cells. Helioxanthin 8-1 can be used in studies related to hepatitis B virus infection .

HY-121513

Torcitabine 2'-Deoxy-L-cytidine; L-dC	HBV	Infection
Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection treatment .

HY-148560B

cis-ccc_R08	HBV	Infection
cis-ccc_R08 (compound 1) is a flavonoid derivative that can be used in the study of **hepatitis B virus (HBV*) infection*. cis-ccc_R08 is a cccDNA (covalently closed circular DNA) inhibitor .

HY-13465

VCH-916 1 Publications Verification	HCV Virus Protease	Infection
VCH-916 is a thiophene derivative and non-nucleoside inhibitor of HCV NS5B polymerase. VCH-916 binds to Thumb Site II. VCH-916 can be used for the research of hepatitis c virus (hcv) infection .

HY-114247

FMAU D-FMAU	Nucleoside Antimetabolite/Analog	Infection Cancer
FMAU is a nucleoside analog and cell proliferation marker that can be phosphorylated by human thymidine kinase and subsequently incorporated into DNA. FMAU is applicable to research related to herpes simplex virus infection, various cancers, hepatitis B virus infection, and Epstein-Barr virus infection .

HY-P991112

Anti-Mouse CD8α Antibody (YTS169.4)	Transmembrane Glycoprotein	Infection
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 ⁺ T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-147266A

Elebsiran VIR-2218	HBV Small Interfering RNA (siRNA)	Infection
Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections .

HY-N0855

Alisol G Alisol-G; 25-Anhydroalisol A	Carboxylesterase (CES) Bacterial HBV	Infection Cancer
Alisol G (25-Anhydroalisol A) is a human carboxylesterase 2 (hCES2) inhibitor with an IC₅₀ of 3.85 μM. Alisol G exhibits cytotoxic activity against human cancer cells, antibacterial activity against Gram-positive strains, and anti-hepatitis B virus activity. Alisol G can be used in research related to lung cancer, breast cancer, prostate cancer, bacterial infections, and HBV infections .

HY-P990828

Anti-PD-L1/B7-H1 Antibody (29E.2A3)	PD-1/PD-L1	Infection
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human *PD-L1/B7-H1. Anti-PD-L1/B7-H1* Antibody (29E.2A3) can block the binding of PD-1 to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV) .

HY-145638

Xalnesiran RO7445482	HBV	Infection
Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection .

HY-P99608

Exbivirumab	HBV	Infection
Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant .

HY-N8107

Matairesinol monoglucoside 2 Publications Verification	STING IFNAR HBV	Infection
Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the STING-TBK1-IRF3 signaling axis, promotes STING transcriptional expression, increases TBK1 and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection .

HY-177300

TLR7/8 agonist 13	Toll-like Receptor (TLR) HBV IFNAR Interleukin Related	Infection Inflammation/Immunology
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .

HY-156578

DGKα-IN-8	DGK HIV	Infection Cancer
DGKα-IN-8 (Example 51) is a DGKα inhibitor (IC₅₀=22.491 nM; EC₅₀=0.256 nM). DGKα-IN-8 can be used to study cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection .

HY-111073

Bentysrepinine Y101	HBV	Infection Inflammation/Immunology
Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields .

HY-148201

Oleana-2,12-dien-28-oic acid	HBV	Infection
Oleana-2,12-dien-28-oic acid is an HBV-DNA inhibitor, HBsAg and HBeAg inhibitor. Oleana-2,12-dien-28-oic acid can be used in hepatitis B virus infection disease research .

HY-N0444R

Rubiadin (Standard)	Reference Standards Reactive Oxygen Species (ROS) Apoptosis Fungal Parasite NF-κB HBV Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rubiadin (Standard) is the analytical standard of Rubiadin (HY-N0444). This product is intended for research and analytical applications. Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections.

HY-19932

MK-2748	HCV Protease HCV	Infection
MK-2748 is a hepatitis C virus (HCV) NS3/4a protease inhibitor. MK-2748 exhibits broad-spectrum and potent antiviral activity, with nanomolar-level activity against all genotypes (gt1a-gt6) (IC₅₀ < 0.115 nM), showing only slightly weaker activity against gt3a (1.212 nM), and maintaining high inhibitory activity against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 can be used in the research of HCV infection .

HY-147255A

(S)-Canocapavir (S)-ZM-H1505R	HBV	Infection
(S)-Canocapavir is the isomer of Canocapavir (HY-147255A). Canocapavir (ZM-H1505R) is an orally active HBV core protein-targeting antiviral agent. Canocapavir binds to the hydrophobic pocket at the dimer-dimer interface of HBV core protein (HBc), stimulating intracellular accumulation of nonfunctional HBV capsids, disrupting viral replication. Canocapavir interferes with the interaction between HBc and HBV large surface protein, resulting in diminished production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection .

HY-169815

HCV NS5B polymerase-IN-2	Virus Protease HCV	Infection
HCV NS5B polymerase-IN-2 (Compound 298) is a Ns5b polymerase inhibitor. HCV NS5B polymerase-IN-2 is promising for research of hepatitis C virus (HCV) infections .

HY-159987

AB-161	HBV	Infection
AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC₅₀ value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research .

HY-13465A

VCH-916 free base	HCV Virus Protease	Infection
VCH-916 free base is a thiophene derivative and non-nucleoside inhibitor of HCV NS5B polymerase. VCH-916 free base binds to Thumb Site II. VCH-916 free base can be used for the research of hepatitis c virus (hcv) infection .

HY-145052

HBV-IN-9	HBV	Infection
HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC₅₀=10 nM) and HBV DNA production inhibitor (IC₅₀=0.15 nM in HepG2.2.15 cells) . From patent WO2018001952A1, example 20.

HY-114956

AT-61	HBV	Infection
AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection .

HY-N19941

Schisanwilsonin K	HBV	Infection
Schisanwilsonin K is a dibenzocyclooctane lignan found in the stems of Schisandra wilsoniana with weak anti-HBV activity.Schisanwilsonin K can be used for the research of hepatitis B virus infection .

HY-145713A

GS-8873 TFA HBV-IN-19 TFA	HBV	Infection
GS-8873 TFA is the TFA salt form of GS-8873 (HY-145713). GS-8873 TFA is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC₅₀ of 4 nM. GS-8873 TFA exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 TFA causes neurofunctional deficits in rats and cynomolgus monkeys .

HY-145713

GS-8873 HBV-IN-19	HBV	Infection
GS-8873 is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC₅₀ of 4 nM. GS-8873 exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 causes neurofunctional deficits in rats and cynomolgus monkeys .

HY-15256A

Faldaprevir sodium BI 201335 sodium	HCV Protease	Infection
Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .

HY-151134

HBV-IN-25	HBV	Infection
HBV-IN-25 is a good potency, orally active novel HBV cccDNA reducer. HBV-IN-25 has anti-HBeAg potency and anti-HBV activity with IC₅₀ values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 has good aqueous solubility (LYSA＞452 μg/mL) and good PK property with no cellular toxicity .

HY-116633

BCM-599	Endogenous Metabolite	Infection
BCM-599 is a HBV (hepatitis B virus) capsid assembly inhibitor with the activity of inhibiting HBV capsid assembly. BCM-599 showed an IC₅₀ value of 0.88μM and a CC50 value of 144μM in HepG2.2.15 cells. When used in combination with lamivudine, BCM-599 showed a synergistic inhibitory effect on viral concentration. BCM-599 can be used as an effective combined inhibition option for HBV infection .

HY-P990236

Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A)	Transmembrane Glycoprotein	Infection Inflammation/Immunology Cancer
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an anti-mouse/rat/monkey/human ICOS/CD278 IgG monoclonal antibody. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) has limited effectiveness in improving T cell function and immune activation. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) can be used for researches on cancer and infection conditions such as gliomas and hepatitis B virus infection .

HY-181347

GLPG3808	HBV	Infection
GLPG3808 is an orally active PAPD5/7 inhibitor. GLPG3808 inhibits the expression of HBcAg in various cells infected with HBV. GLPG3808 reduces the hepatitis B surface antigen levels in HBV-infected animal models. GLPG3808 can be used for the research of hepatitis B virus infection .

HY-108839

Peginterferon alfa-2a Ro 25-8310/000	IFNAR	Infection
Peginterferon alfa-2a is a PEG-modified interferon (IFN) alpha-2a. Peginterferon alfa-2a can be used for research of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection .

HY-169125

HBV-IN-49	HBV	Infection
HBV-IN-49 is an anti-hepatitis B virus (HBV) agent that inhibits HBV replication. HBV-IN-49 can be utilized in infection research .

Cat. No.	Product Name	Type

HY-142989

1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine

Biochemical Assay Reagents

1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia .

Cat. No.	Product Name	Target	Research Area

HY-P10056

HEP-1 Human ezrin peptide (324-337)	HIV HCV HPV Influenza Virus Interleukin Related	Infection Inflammation/Immunology
HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-P99693

Lenvervimab GC1102	HBV	Infection
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .

HY-P991112

Anti-Mouse CD8α Antibody (YTS169.4)	Transmembrane Glycoprotein	Infection
Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 ⁺ T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-P990828

Anti-PD-L1/B7-H1 Antibody (29E.2A3)	PD-1/PD-L1	Infection
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human *PD-L1/B7-H1. Anti-PD-L1/B7-H1* Antibody (29E.2A3) can block the binding of PD-1 to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV) .

HY-P99608

Exbivirumab	HBV	Infection
Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab (HY-P99703) decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant .

HY-P990236

Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A)	Transmembrane Glycoprotein	Infection Inflammation/Immunology Cancer
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an anti-mouse/rat/monkey/human ICOS/CD278 IgG monoclonal antibody. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) has limited effectiveness in improving T cell function and immune activation. Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) can be used for researches on cancer and infection conditions such as gliomas and hepatitis B virus infection .

HY-108839

Peginterferon alfa-2a Ro 25-8310/000	IFNAR	Infection
Peginterferon alfa-2a is a PEG-modified interferon (IFN) alpha-2a. Peginterferon alfa-2a can be used for research of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection .

HY-P992458

SBT8230	Toll-like Receptor (TLR) HBV	Infection
SBT8230 is an ASGR1-targeted TLR8 agonist and an ASGR1-TLR8 immune TAC conjugate. SBT8230 achieves liver enrichment via conjugation with an anti-ASGR1 antibody, activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. The corresponding isotype control is: Human lgG1 kappa,lsotype Control (HY-P99001) .

Cat. No.	Product Name		Classification

HY-145638A

Xalnesiran sodium RO7445482 sodium		siRNAs siRNA drugs
Xalnesiran (RO7445482) sodium is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome . Xalnesiran sodium can be used for the research of chronic hepatitis B infection .

HY-147266

Elebsiran sodium VIR-2218 sodium		siRNAs siRNA drugs
Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .

HY-142989

1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine		Phospholipids
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia .

HY-W352344

2'-Deoxy-L-adenosine		Nucleoside Analogs Adenosine
2'-Deoxy-L-adenosine is an orally active synthon for modified oligodeoxyribonucleotides. 2'-Deoxy-L-adenosine is a potent, specific and selective inhibitor of the replication of hepatitis B virus (HBV) as well as the closely related duck and woodchuck hepatitis viruses (WHV) .

HY-121513

Torcitabine 2'-Deoxy-L-cytidine; L-dC		Nucleoside Analogs Cytidine
Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection treatment .

HY-145638

Xalnesiran RO7445482		siRNAs siRNA drugs
Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

hepatitis B virus infection

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products